|
|
| | 2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide Basic information |
| | 2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide Chemical Properties |
| density | 1.78±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 8.12±0.10(Predicted) |
| | 2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide Usage And Synthesis |
| Uses | mTOR/HDAC-IN-1 (Compound 50) is a selective mTOR and HDAC dual inhibitor with IC50 values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an anti-cancer agent[1]. | | IC 50 | mTOR: 0.49 nM (IC50); HDAC1: 0.91 nM (IC50); HDAC6: 86 nM (IC50); HDAC8: 27 nM (IC50) | | References | [1] Mingming Zhang, et al. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorg Med Chem Lett. 2021 Oct 1;49:128286. DOI:10.1016/j.bmcl.2021.128286 |
| | 2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide Preparation Products And Raw materials |
|